Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$3.8B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Kiniksa aims to address unmet medical needs through its research and development efforts.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating expectations of $0.18, which led to a positive stock reaction of +23.48% the following day. However, revenue figures were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating another strong performance from Kiniksa, especially after the positive surprise in the last quarter. However, the lack of revenue guidance raises concerns about the sustainability of this growth.

Bull Case

If Kiniksa continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to further stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure is crucial as it will indicate the company's profitability and could significantly impact investor sentiment.

Will Kiniksa provide any revenue guidance for the upcoming quarters?

Revenue guidance will help investors assess the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to sustain its EPS growth due to its recent product developments and market positioning.

Supporting Evidence

Kiniksa's recent EPS surprise of +50% indicates strong operational execution.

The options market pricing suggests high volatility, which could reflect underlying positive sentiment not captured in consensus estimates.

Key Risk

If EPS comes in below $0.20, it could undermine the positive narrative around the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kiniksa can maintain its recent earnings momentum amidst uncertain revenue prospects.

Bull Confirmed If

A Q2-2026 EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.20 would signal potential issues in profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move of about 24.6%, indicating that traders expect volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations and raises guidance, history suggests a potential stock increase of around +19.81%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline of about -6.58%, which could trigger a sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected timelines.
2Insights into market demand for Kiniksa's therapies and any new partnerships.
3Management's outlook on revenue growth and market conditions.
4Details on cost management and operational efficiency improvements.
5Responses to competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kiniksa continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to further stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure is crucial as it will indicate the company's profitability and could significantly impact investor sentiment.

Will Kiniksa provide any revenue guidance for the upcoming quarters?

Revenue guidance will help investors assess the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to sustain its EPS growth due to its recent product developments and market positioning.

Supporting Evidence

Kiniksa's recent EPS surprise of +50% indicates strong operational execution.

The options market pricing suggests high volatility, which could reflect underlying positive sentiment not captured in consensus estimates.

Key Risk

If EPS comes in below $0.20, it could undermine the positive narrative around the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kiniksa can maintain its recent earnings momentum amidst uncertain revenue prospects.

Bull Confirmed If

A Q2-2026 EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.20 would signal potential issues in profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move of about 24.6%, indicating that traders expect volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations and raises guidance, history suggests a potential stock increase of around +19.81%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline of about -6.58%, which could trigger a sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected timelines.
2Insights into market demand for Kiniksa's therapies and any new partnerships.
3Management's outlook on revenue growth and market conditions.
4Details on cost management and operational efficiency improvements.
5Responses to competitive pressures in the biotechnology sector.